{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Hepatitis&page=2", "query": { "condition": "Chronic Hepatitis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Hepatitis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T04:06:48.429Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00275652", "title": "A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B", "Cirrhosis" ], "interventions": [ { "name": "LdT (Telbivudine) and lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2004-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2011-03-23", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00275652" }, { "nct_id": "NCT01728324", "title": "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "BI 207127-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 24-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 24-week treatment", "type": "DRUG" }, { "name": "Ribavirin-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir-placebo: 8-week treatment", "type": "DRUG" }, { "name": "Faldaprevir: 16-week treatment", "type": "DRUG" }, { "name": "Ribavirin: 16-week treatment", "type": "DRUG" }, { "name": "RBV: 24-week treatment", "type": "DRUG" }, { "name": "BI 207127: 16-week treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 496, "start_date": "2012-11", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 31, "location_summary": "North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01728324" }, { "nct_id": "NCT00439959", "title": "Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic", "Hepatitis C" ], "interventions": [ { "name": "GSK625433/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2006-10", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439959" }, { "nct_id": "NCT01356160", "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "GS-9451 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 351, "start_date": "2011-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 21, "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356160" }, { "nct_id": "NCT00867243", "title": "Prediction of Hepatitis C Recurrence in Liver Transplant Recipients", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Complication of Transplanted Liver", "Hepatitis C, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-06-11", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867243" }, { "nct_id": "NCT06907290", "title": "A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Hepatitis D Infection" ], "interventions": [ { "name": "Brelovitug 300 mg", "type": "DRUG" }, { "name": "Brelovitug 900 mg", "type": "DRUG" }, { "name": "Delayed Treatment with Brelovitug 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-03-25", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 15, "location_summary": "Garden Grove, California • Huntington Beach, California • Long Beach, California + 9 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907290" }, { "nct_id": "NCT00322179", "title": "Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Hepatitis C", "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Palo Alto Veterans Institute for Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-11", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00322179" }, { "nct_id": "NCT01732796", "title": "IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BI 201335 (Faldaprevir)", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "Faldaprevir (BI 201335)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 470, "start_date": "2012-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 24, "location_summary": "Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732796" }, { "nct_id": "NCT00771446", "title": "Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Hepatitis", "Chronic Hepatitis" ], "interventions": [ { "name": "ELAD plus standard of care treatment", "type": "BIOLOGICAL" }, { "name": "Standard of care treatment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vital Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "19 Years to 69 Years" }, "enrollment_count": 18, "start_date": "2008-10", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 6, "location_summary": "La Jolla, California • San Francisco, California • Chicago, Illinois + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00771446" }, { "nct_id": "NCT02215902", "title": "Safety Study of the Aethlon Hemopurifier", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "End Stage Renal Disease", "Hepatitis C Infection" ], "interventions": [ { "name": "Affinity plasmapheresis", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Aethlon Medical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-12", "completion_date": "2017-03-10", "has_results": false, "last_update_posted_date": "2017-03-14", "last_synced_at": "2026-06-27T04:06:48.429Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02215902" } ] }